IRCT20200623047902N24Not yet recruiting未知
Bioequivalence study of ?Baricitinib 4mg manufactured by Alborzzagros versus originator brand in healthy volunteers in the fasted condition
Alborz Zagros company0 sites24 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 55 years (—)
- Sex
- All
Inclusion Criteria
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to baricitinib
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Study of absorption and elimination rate of Ibrutinib 140 -mg Capsules in comparison with Ibrutinib brand capsules (Imbruvica®)IRCT20200407046981N43Kimia pharmaceutical Co24
Recruiting
Phase 3
Evaluation of therapeutic effect of baricitinib in patients with severe pneumonia requiring non-invasive ventilation induced to Covid 19Acute viral infection caused by the corona virus (COVID-19).COVID-19, virus identifiedU07.1IRCT20220508054780N1Mashhad University of Medical Sciences15
Unknown
Phase 2
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)-I4V-MC-JAHHJPRN-jRCT2080223304Eli Lilly Japan K.K.
Recruiting
Not Applicable
Bioequivalence study of Nilotinib 200mg capsuleThis study is performed on healthy volunteers..IRCT20200623047902N21Zistdaru danesh Co.24
Not yet recruiting
Not Applicable
Bioequivalence study of Nilotinib 200mg capsuleThis study is performed on healthy volunteers..IRCT20200623047902N17Rooyan darou company24